TABLE 2.
Diagnosis | Primary | Secondary | Tertiary |
---|---|---|---|
n (%) | n (%) | n (%) | |
Agoraphobia | 0 (0.00) | 3 (0.22) | 3 (0.22) |
Anxiety | 120 (8.71) | 111 (8.06) | 25 (1.81) |
Attention‐deficit/hyperactivity disorder | 22 (1.60) | 14 (1.02) | 3 (0.22) |
Autistic spectrum disorder | 19 (1.38) | 8 (0.58) | 12 (0.87) |
Cancer pain | 11 (0.80) | 7 (0.51) | 0 (0.00) |
Chemotherapy‐induced nausea and vomiting | 6 (0.44) | 1 (0.07) | 1 (0.07) |
Chronic non‐cancer pain | 394 (28.59) | 80 (5.81) | 1 (0.94) |
Cluster headaches | 3 (0.22) | 1 (0.07) | 0 (0.00) |
Complex regional pain syndrome | 8 (0.58) | 3 (0.22) | 2 (0.15) |
Crohn's disease | 27 (1.96) | 5 (0.36) | 2 (0.15) |
Depression | 54 (3.92) | 50 (3.63) | 34 (2.47) |
Eating disorder | 1 (0.07) | 3 (0.22) | 4 (0.29) |
Ehlers‐Danlos Syndrome | 42 (3.05) | 23 (1.67) | 9 (0.65) |
Endometriosis | 1 (0.07) | 1 (0.07) | 0 (0.00) |
Epilepsy adult | 26 (1.89) | 1 (0.07) | 1 (0.07) |
Fibromyalgia | 162 (11.76) | 73 (5.30) | 7 (0.51) |
Headache | 2 (0.15) | 8 (0.58) | 2 (0.15) |
Inflammatory arthritis | 52 (3.77) | 0 (0.00) | 0 (0.00) |
Insomnia | 30 (2.18) | 31 (2.25) | 22 (1.60) |
Migraine | 38 (2.76) | 20 (1.45) | 8 (0.58) |
Multiple sclerosis | 36 (2.61) | 3 (0.22) | 0 (0.00) |
Neuropathic pain | 136 (9.87) | 49 (3.56) | 7 (0.51) |
Obsessive‐compulsive disorder | 2 (0.15) | 3 (0.22) | 1 (0.07) |
Osteoarthritis | 51 (3.70) | 5 (0.36) | 4 (0.29) |
Palliative care | 55 (3.99) | 1 (0.07) | 0 (0.00) |
Parkinson's | 12 (0.87) | 1 (0.07) | 0 (0.00) |
Post‐traumatic stress disorder | 54 (3.92) | 3 (0.22) | 10 (0.73) |
Rare and challenging skin condition | 5 (0.36) | 13 (0.94) | 0 (0.00) |
Tourette's syndrome | 2 (0.15) | 3 (0.22) | 0 (0.00) |
Trigeminal neuralgia | 1 (0.07) | 3 (0.22) | 1 (0.07) |
Ulcerative colitis | 6 (0.44) | 3 (0.07) | 0 (0.00) |
Note: The indications for cannabis‐based medicinal product treatment and the number of patients with the corresponding indication were recorded.
Abbreviation: n, number of patients.